{"id":"terconazole-vaginal-suppository","safety":{"commonSideEffects":[{"rate":"5-10","effect":"Vulvovaginal irritation or burning"},{"rate":"2-5","effect":"Headache"},{"rate":"2-5","effect":"Abdominal pain or cramping"},{"rate":"5-10","effect":"Vulvovaginal pruritus"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Terconazole is an azole antifungal that selectively inhibits the cytochrome P450-dependent enzyme lanosterol 14α-demethylase in fungal cells. This blocks the conversion of lanosterol to ergosterol, a critical component of the fungal cell membrane. The resulting membrane instability and leakage of cellular contents leads to fungal cell death, making it effective against vaginal candidiasis.","oneSentence":"Terconazole inhibits fungal cell membrane synthesis by blocking lanosterol 14α-demethylase, disrupting ergosterol production in Candida species.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T00:11:46.987Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Vulvovaginal candidiasis (yeast infection)"}]},"trialDetails":[{"nctId":"NCT00803738","phase":"NA","title":"Safety and Equivalence of a Terconazole Vaginal Suppository (Test Product) Compared to the Reference Terconazole Vaginal Suppository in the Treatment of Vulvovaginal Candidiasis","status":"COMPLETED","sponsor":"Padagis LLC","startDate":"2002-12","conditions":"Vulvovaginal Candidiasis","enrollment":572},{"nctId":"NCT02180100","phase":"PHASE4","title":"Terconazole Vaginal Suppository vs Fluconazole for the Treatment of Severe Vulvovaginal Candidiasis","status":"COMPLETED","sponsor":"Peking University Shenzhen Hospital","startDate":"2013-08","conditions":"Vulvovaginal Candidiasis","enrollment":140},{"nctId":"NCT04208555","phase":"NA","title":"Comparison of Boric Acid vs. Terconazole in Treatment of RVVC","status":"UNKNOWN","sponsor":"Hatem AbuHashim","startDate":"2020-01-15","conditions":"Vulvovaginal Candidiasis","enrollment":76}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":5,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["Tekangzuo Yindao Shuan"],"phase":"marketed","status":"active","brandName":"Terconazole Vaginal Suppository","genericName":"Terconazole Vaginal Suppository","companyName":"Hatem AbuHashim","companyId":"hatem-abuhashim","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Terconazole inhibits fungal cell membrane synthesis by blocking lanosterol 14α-demethylase, disrupting ergosterol production in Candida species. Used for Vulvovaginal candidiasis (yeast infection).","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":1,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}